[Endogenous Candida endophthalmitis combined with severe general diseases].
BACKGROUND
Endogenous Candida endophthalmitis is a rare disease with increasing frequency and poor prognosis.


METHODS
The course of endogenous Candida endophthalmitis in 7 eyes of 5 patients (age 2 months to 76 years) was evaluated. Underlying general diseases were diagnosed as colon cancer, diverticulitis, pancreatic insufficiency (with subclavian catheter), ileus and diabetes mellitus. Diagnosis was based on the very typical ocular feature combined with a positive blood or vitreous culture. Intensive antimycotic drug therapy was initiated and pars plana vitrectomy performed as soon as possible.


RESULTS
The delay between onset of ocular symptoms and diagnosis amounted to one week and 2 months. In 3 eyes of 2 patients no vitrectomy could be done because of the very impaired state of health. These patients died of their general diseases one week and 2 months, respectively, later. During follow-up (4 weeks to 51 months) three eyes reached visual acuity of 5/10, 4/10 and 1/10. One eye reached 1/20 after additional surgery because of retinal detachment. In all vitrectomized eyes the diagnosis was substantiated by a positive culture of vitreous fluid. No recurrence of ocular inflammation was observed.


CONCLUSIONS
Early vitrectomy seems to be mandatory in each case which is suspected of Candida endophthalmitis. Only with this option it is possible to fix the diagnosis and initiate adequate therapy in due time in order to improve the original poor prognosis.
Stoffelns
B M
BM
Augenklinik der Johannes Gutenberg-Universität, Mainz. stoffelns@augen.klinik.uni-mainz.de
D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage; D000867:Anterior Chamber; D000935:Antifungal Agents / Q000008:administration & dosage; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D009877:Endophthalmitis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D005260:Female; D016469:Fungemia / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D005839:Gentamicins / Q000008:administration & dosage; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D007267:Injections; D008297:Male; D009883:Ophthalmic Solutions; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage; D012307:Risk Factors; D016896:Treatment Outcome; D014821:Vitrectomy; D014822:Vitreous Body
D000935:Antifungal Agents; D005839:Gentamicins; D009883:Ophthalmic Solutions; D000666:Amphotericin B; D011241:Prednisone